Assoc. Prof. Erkan Kayikcioglu

Assoc. Prof. Erkan Kayikcioglu
Academic Title :
Assoc. Prof.

Assoc. Prof. Erkan Kayikcioglu is a highly experienced Medical Oncology specialist at Liv Hospital Bahcesehir. He possesses over 15 years of clinical and academic expertise in diagnosing and treating various types of cancers, with a particular focus on personalized medicine and immunotherapy.

Education and Academic Qualifications

  • Graduated from Hacettepe University Faculty of Medicine (English program)
  • Specialization in Internal Medicine, Selcuk University Meram Faculty of Medicine
  • Specialization in Medical Oncology, Antalya Training and Research Hospital

Areas of Interest

  • Personalized Medicine
  • Immunotherapy
  • Breast Cancer
  • Lung Cancer
  • Colon Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Liver Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • 2010 - 2013: Internal Medicine Specialist at Seydisehir State Hospital
  • 2013 - 2015: Internal Medicine Specialist at Antalya Private Yasam Hospital
  • 2015 - 2018: Medical Oncology Fellow at University of Health Sciences Antalya Training and Research Hospital
  • 2018 - 2020: Medical Oncology Specialist at Recep Tayyip Erdogan University Faculty of Medicine
  • 2020 - 2021: Medical Oncology Specialist at University of Health Sciences Antalya Training and Research Hospital
  • 2021 - 2023: Faculty Member at Suleyman Demirel University Faculty of Medicine
  • 2023 - Present: Medical Oncology Specialist at Liv Hospital Bahcesehir (Istinye University)
  • Member of the European Society for Medical Oncology (ESMO) since 2022
  • Member of the Turkish Society of Medical Oncology (TTOD) since 2015
  • The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes (Medicine, 2023)
  • Prognostic value of claudin 18.2 expression in gastric adenocarcinoma (World Journal of Gastrointestinal Oncology, 2023)
  • Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (BMC Cancer, 2023)
  • Machine learning for predicting colon cancer recurrence (Surgical Oncology, 2024)
  • Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Advanced Pancreatic Cancer (2024)
Share :